VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

Novo Nordisk shares fell due to a supply issue in the US, disappointing trial results for its new weight loss drug CagriSema, and heightened competition. The trust declared an interim dividend of 1.4p ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...